


# Author Index

VOLUME 19, 2001

- Abrams, Larry S., 373  
Adashi, Eli Y., 3, 167  
Alsip, Nancy L., 75
- Barnhart, Kurt T., 295  
Beever, C., 175  
Bischof, P., 49  
Blumenthal, Paul D., 313  
Bodek, G., 19  
Brown, Carolyn J., 123, 125, 175  
Burke, Anne E., 313
- Carr, Bruce R., 121, 203, 291  
Cohen, Jean, 205, 269  
Collins, John, 279  
Cortes, Laura Salas, 133  
Creasy, George W., 373  
Creinin, Mitchell D., 305
- Darney, Philip D., 339  
Davis, Owen K., 207  
Dayal, Molina, 295  
Derecka, K., 19  
de Ziegler, Dominique, 31  
Dhont, Marc, 251  
Diedrich, K., 213  
Disteche, Christine M., 147
- Ellertson, Charlotte, 323  
Esplin, Michael S., 167
- Fanchin, Renato, 31  
Fazleabas, Asgerally T., 69  
Felberbaum, R.E., 213  
Fields, Michael J., 87  
Fisher, Alan C., 373  
Frydman, René, 31
- Gardner, David K., 259  
Gawronska, B., 19  
Ghinea, Nicolae, 97  
Grimes, David A., 293  
Gurevich, Michael, 87
- Harwood, Bryna, 381
- Islami, D., 49
- Jones, Jr., Howard W., 205, 269
- Kaunitz, Andrew M., 293, 331  
Kenneson, Aileen, 159  
Koenig, Jacqueline, 323  
Kurtzman, James T., 63
- Lei, Z.M., 103  
Leppig, Kathleen A., 147  
Licht, P., 37  
Lobo, Shalini C., 69  
Ludwig, M., 213  
Lukács, Hedvig, 111  
Luukkainen, Tapani, 355, 365
- McElreavey, Ken, 133  
Meckstroth, Karen R., 339  
Milgrom, Edwin, 97  
Mishell, Jr., Daniel R., 381  
Mizrachi, Dario, 87  
Mock, P., 49
- Oehninger, Sergio, 231
- Pakarinen, Päivi, 355, 365  
Peltier, Eric, 31  
Peng, Xinjiang, 69
- Porcu, Eleonora, 221  
Pymar, Helen C., 305
- Rao, C.V., 5, 7, 63, 75, 103  
Raymond, Elizabeth G., 323  
Robinson, W.P., 175  
Rosenwaks, Zev, 207  
Ross, Judith L., 141  
Russu, V., 37
- Samango-Sprouse, Carole, 193  
Schoolcraft, William B., 259  
Shemesh Mordechai, 87  
Shochet, Tara, 323  
Shore, Laurence S., 87  
Simpson, Joe Leigh, 123, 239  
Stephenson, M.D., 175  
Stepien, A., 19  
Stewart, Felicia, 323  
Stram, Yehuda, 87  
Srisuparp, Santha, 69
- Tavares Adriano B., 167  
Toivonen, Juhani, 355, 365  
Toth, Peter, 55  
Trussell, James, 323
- Van den Veyver, Ignatia B., 183
- Warren, Stephen T., 159  
Wildt, L., 37  
Wilson, H., 63
- Ziecik, A.J., 19  
Zinn, Andrew R., 141



# Subject Index

VOLUME 19, 2001

- Abortion  
spontaneous, intracytoplasmic sperm injection (ICSI), genetic effects, 240–247  
spontaneous recurrent, skewed X inactivation and, 175–180  
threatened abortion, uterine blood vessels, LH/hCG receptors in, 55–60
- Adenomyosis, levonorgestrel-releasing intrauterine system (LNG-IUS) for management of, 369–371
- Adenylate cyclase, LH activation, bovine models, 89–94
- Adherence, transdermal contraception and efficacy of, 373–379
- Adolescent patients  
implant contraception in, 344–349  
oral contraceptive use and compliance rates, 313–320
- Age, maternal, assisted reproductive technologies, multiple pregnancies, avoidance of, 271–277
- Amino acids, embryo transfer, blastocyst *vs.* day 2 or 3 transfer, 259–266
- Aneuploidy  
polysomy X Klinefelter syndrome, 200–201  
recurrent spontaneous abortion, X chromosome inactivation, 175–180
- Angiogenesis, rat models, uterine blood vessels, LH/hCG effects on, 80–81
- Animal models  
baboon uterine receptivity, chorionic gonadotropin (CG) and, 72–73  
bovine myometrium and cervix, LH and FSH receptors, 87–94  
pig and human studies, parallels in, gonadotropin regulation, nongonadal tissue, 19–27  
rat models  
behavioral effects of hCG, 111–118  
LH/hCG effects on uterine blood flow, 75–81
- Anxiety, rat models, behavioral effects of hCG and, 111–118
- Assisted reproductive technologies (ART)  
blastocyst *vs.* embryo transfer, 259–266  
cost-effectiveness of in vitro fertilization, 279–287  
intracytoplasmic sperm injection (ICSI), genetic effects, 239–247  
male infertility strategies, 231–235  
multiple pregnancies, avoidance of, 269–277  
oocyte freezing, 221–228  
research overview, 205  
single-embryo transfer, 251–257  
superovulation strategies, 207–211  
in vitro fertilization, gonadotropin-releasing hormone antagonists and, 213–219
- Azoospermia, strategies for management of, 231–235
- Baboon studies, uterine receptivity, chorionic gonadotropin (CG) and, 69–73
- Behavior  
Klinefelter syndrome, neurodevelopmental abnormalities, 193–201  
LH/hCG receptors, neural action of, 105–107  
rat models, human chorionic gonadotropin (hCG) effect on, 111–118
- Benign breast disease, oral contraceptives and reduction of, 296
- Blastocyst transfer, embryo transfer, blastocyst *vs.* day 2 or 3 transfer, 259–266
- Blood flow resistance  
rat models, uterine blood vessels, LH/hCG effects on, 75–81  
uterine blood vessels, LH/hCG receptors in, 55–60
- BMP15* gene, premature ovarian failure, 144–145
- Bone mineral density  
implant contraception and, 345–346  
injectable contraceptives and possible loss of, 332–335  
oral contraceptives and preservation of, 298–301
- Bovine models, myometrium and cervix, LH and FSH receptors, 87–94
- Brain, LH/hCG neural actions in, 103–107
- Breast cancer  
levonorgestrel-releasing intrauterine system (LNG-IUS) combined with tamoxifen treatment, 370–371  
LH/hCG receptor function and, 10–12  
oral contraceptive use and risk of, 310–311
- Broad ligament, LH/hCG receptors in, 22–24
- Cancer. *See also* Breast cancer; Ovarian cancer; Uterine cancer  
injectable contraceptives and risk of, 332–335  
LH/hCG receptor function and, 7–12
- Carbohydrates, embryo transfer, blastocyst *vs.* day 2 or 3 transfer, 259–266
- Cardiovascular disease  
injectable contraceptives and risk of, 332–335  
oral contraceptive use and risk of, 305–311
- cDNA  
microarray, ovarian genes, 169–172  
representational difference analysis (RDA), ovarian genes, 169–172

- Central nervous system (CNS), LH/hCG neural actions and, 103-107
- Cervix  
bovine models, FSH receptors, 87-94  
contraceptive vaginal rings (CVRs), effects on, 387-388  
implant contraception and mucus changes in, 342  
LH/hCG receptors in, 26
- Cetrorelix, in vitro fertilization, gonadotropin-releasing hormone (GnRH) antagonists, 213-219
- Chorionic gonadotropin (CG), uterine receptivity in baboons and, 69-73
- Chromosome. *See* X chromosome; Y chromosome
- Chromosome damage  
intracytoplasmic sperm injection (ICSI), genetic effects, 239-247  
oocyte freezing technology, 226-228
- Clomiphene challenge test (CCCT), superovulation strategies, assisted reproductive technologies (ART), 209-211
- Clomiphene citrate (CC), superovulation strategies, assisted reproductive technologies (ART), 207-211
- Cluster analysis, ovarian gene identification, 170-172
- Cognition, polysomy X Klinefelter syndrome, 193-201
- Colorectal cancer, oral contraceptives as protection from, 299
- Compliance studies  
oral contraceptive use and compliance rates, 313-320  
transdermal contraception, 373-379
- Congenital bilateral absence vas deferens (CBAVD), intracytoplasmic sperm injection (ICSI), 244-247
- Connexin (CX) proteins, human chorionic gonadotropin receptor function and, 65-66
- Contraception. *See* Hormonal contraception; specific types of contraception
- Contraceptive vaginal rings (CVRs), risks and benefits of, 381-388
- Controlled ovarian hyperstimulation (COH)  
in vitro fertilization, gonadotropin-releasing hormone (GnRH) antagonists, 213-219  
in vivo endometrial morphology, human chorionic gonadotropin and, 31-35
- Copper-T intrauterine device, emergency contraception using, 323-329
- Corpus luteum (CL), human chorionic gonadotropin (hCG) invasion, trophoblast invasion compared with, 52
- Cortical granules, oocyte freezing technology, 226-228
- Cost-effectiveness analysis  
emergency contraception, 328  
implant contraception, 343-349  
in vitro fertilization, 279-287
- Cryopreservation  
cost-effectiveness of in vitro fertilization and, 282-287  
multiple pregnancies, avoidance of, in assisted reproductive technologies, 269-277  
oocyte freezing, 221-228
- Cryoprotectants, oocyte freezing technology and, 225-228
- Culture protocols, embryo transfer, blastocyst *vs.* day 2 or 3 transfer, 261-266
- Cumulus oophorus, oocyte freezing technology and, 225-228
- Cyclooxygenase, LH activation, bovine models, 91-94
- Cystic fibrosis transmembrane regulator (CFTR) gene, intracytoplasmic sperm injection (ICSI), genetic effects, 244-247
- Cytokines  
human chorionic gonadotropin (hCG) in embryo-endometrial microenvironment, differentiation and implantation, 37-46  
human chorionic gonadotropin receptor function and, 65-66
- Cytoskeleton, oocyte freezing technology, 226-228
- Cytotrophoblast (CTB), human chorionic gonadotropin (hCG) invasion, 49-52
- Depo-Provera, injectable contraception using, 331-335
- Depot medroxyprogesterone acetate (DMPA), injectable contraception using, 331-335
- Developmental abnormalities, polysomy X Klinefelter syndrome, 193-201
- DLAPH2* gene, ring X abnormality, 148-154
- Differential display (DD), ovarian genes, identification strategies, 168-172
- Differential hybridization, ovarian genes, identification strategies, 167-172
- Differential methylation, skewed X-chromosome inactivation, X-linked disorders, 184-189
- Differentiation, human chorionic gonadotropin (hCG) in embryo-endometrial microenvironment, 37-46
- Dosage compensation, X chromosome inactivation, 125-129
- Double-embryo transfer  
assisted reproductive technologies, multiple pregnancies, avoidance of, 272-277  
techniques for, 252-257
- Downstream cost analysis, in vitro fertilization, cost-effectiveness, 284-287
- Economic analysis, in vitro fertilization, cost-effectiveness, 279-287
- Ectopic pregnancy  
implant contraception as protection against, 342-343  
oral contraceptives and protection against, 298
- EDHF activity, rat models, uterine blood vessels, LH/hCG effects on, 81
- Eicosanoid, LH/hCG receptors, neural action of, 106-107
- Embryo  
implantation, in vivo endometrial morphology, human chorionic gonadotropin and, 31-35  
reduction, in multiple pregnancies, 275-277  
transfer  
blastocyst *vs.* day 2 or 3 transfer, 259-266  
cost-effectiveness of in vitro fertilization and, 282-287  
multiple pregnancies, avoidance of, 269-277  
single-embryo transfer, multiple pregnancies, 251-257
- Emergency contraception  
barriers to, 326-329  
combined emergency contraceptive pills (ECPS), 323-329  
guidelines for, 323-329  
oral contraceptive use and compliance and, 313-320
- Endocrine organs, luteinizing hormone (LH) receptors, 3
- Endometrial receptivity  
human chorionic gonadotropin (hCG) in embryo-endometrial microenvironment, differentiation and implantation, 37-46  
in vivo endometrial morphology, human chorionic gonadotropin and, 31-35

- Endometriosis  
  levonorgestrel-releasing intrauterine system (LNG-IUS)  
  for management of, 369-371  
  oral contraceptives and protection against, 300
- Endometrium  
  implant contraception and changes in, 342  
  LH/hCG receptors in, 24-25  
  progesterin-releasing intrauterine systems and, 355-361  
  secretory products of, 51-52  
  in vivo morphology, human chorionic gonadotropin and,  
  31-35
- Endothelial cells, LH/CG receptor transcytosis, barrier in  
  target organs, 97-100
- Estradiol cypionate, injectable contraception using, 331-335
- Ethics, of implant contraception use, 349
- Ethinyl estradiol, contraceptive vaginal rings (CVRs) using,  
  384-388
- Etonogestrel, contraceptive vaginal rings (CVRs) using,  
  385-388
- Evra, transdermal contraception using, 373-379
- Exogenous estradiol, in vivo endometrial morphology, human  
  chorionic gonadotropin and, 31-35
- Extracellular signal-regulated protein kinase (ERK), baboon  
  models, uterine receptivity, chorionic gonadotropin  
  modulation, 71-73
- Female patients, fragile X syndrome genetics in, 159-163
- Fetal development, LH/hCG receptors, neural action of,  
  103-107
- FMRI* gene, fragile X syndrome in females, 159-163
- FMRP protein, *FMRI*, fragile X syndrome in females, 159-163
- Follicle-stimulating hormone (FSH) receptors  
  bovine models, cervical FSH receptors, 87-94  
  fragile X syndrome in females, 161-163  
  superovulation strategies, assisted reproductive  
  technologies (ART), 208-211
- Follicular atresia, recurrent spontaneous abortion, X  
  chromosome inactivation, 175-180
- Follicular hypertrophy, implant contraception and, 346
- Fragile X syndrome, female patients, 159-163
- FSH. *See* Follicle-stimulating hormone (FSH) receptors
- Ganirelix, in vitro fertilization, gonadotropin-releasing  
  hormone (GnRH) antagonists, 213-219
- Gene  
  *BMP15*, premature ovarian failure, 144-145  
  *FMRI*, fragile X syndrome in females, 159-163  
  ovarian genes, identification strategies, 167-172  
  *PKRX* and *PKRY*, X-Y chromosome translocation,  
  133-138  
  *SHOX*  
  ring X abnormality, X chromosome, inactivation and  
  phenotype, 148-154  
  Turner syndrome and premature ovarian failure,  
  molecular analysis, 141-145  
  *SRY* gene, X-Y chromosome translocation, 133-138  
  *USP9X*, premature ovarian failure and, 143-145
- Gene expression  
  luteinizing hormone receptors, 20-23  
  ovarian genes, differential hybridization, other  
  identification strategies, 167-172  
  X chromosome inactivation, 126-129
- Genetics  
  spontaneous, intracytoplasmic sperm injection (ICSI),  
  239-247  
  variants, nonrandom X chromosome inactivation, 126-129
- Genotype-phenotype relationships, X-Y chromosome  
  translocation, 137-138
- Glycoproteins  
  human chorionic gonadotropin (hCG), trophoblast  
  invasion, 51-52  
  LH/CG receptors, transendothelial transport, 98-100
- GnRH. *See* Gonadotropin-releasing hormone (GnRH)  
  antagonists
- Gonadal development, X-Y chromosome translocation,  
  133-138
- Gonadotropin-releasing hormone (GnRH) antagonists, in  
  vitro fertilization and, 213-219
- Gonadotropins  
  embryo-endometrial microenvironment, differentiation  
  and implantation, 37-46  
  neural actions of, 103-107  
  nongonadal tissue regulation, 5  
  research overview, 7-12  
  superovulation strategies, assisted reproductive  
  technologies (ART), 207-211
- Gonadotropin two-cell theory, luteinizing hormone (LH)  
  receptor, 3
- G proteins  
  baboon models, uterine receptivity, chorionic gonadotropin  
  modulation, 69-73  
  bovine models, myometrium and cervical LH and FSH  
  receptors, 87-94
- Gynecological disease, LH/hCG receptor function and, 7-12
- hCG. *See* Human chorionic gonadotropin (hCG)
- Hemizoma assay (HZA), male infertility strategies, 232-235
- Hermaphroditism, X-Y chromosome translocation, 133-138
- Heterochromatin, X chromosome inactivation, 127-129
- High-responder stimulation, superovulation strategies,  
  assisted reproductive technologies (ART), 210-211
- Hormonal contraception  
  contraceptive vaginal rings (CVRs), 381-388  
  emergency contraception, 323-329  
  implant contraception, 339-349  
  injectable contraception options, 331-335  
  noncontraceptive benefits and therapeutic uses, 295-301  
  progesterin-releasing intrauterine systems  
  risks and benefits, 355-361  
  therapeutic applications, 365-371  
  research overview, 293-294  
  risk studies of oral contraceptives, 305-311  
  transdermal contraception, 373-379
- Hormone replacement therapy (HRT), levonorgestrel-  
  releasing intrauterine system (LNG-IUS) for,  
  365-371
- Human chorionic gonadotropin (hCG). *See also* Chorionic  
  gonadotropin (CG)  
  embryo-endometrial microenvironment, differentiation  
  and implantation, 37-46  
  neural actions, 103-107  
  nongonadal tissue regulation, 5  
  research overview, 7-12  
  pig and human studies, parallels in, 19-27

- Human chorionic gonadotropin (hCG) (*cont.*)  
 rat models  
   behavior effects of, 111-118  
   uterine blood vessels, LH/hCG effects on, 75-81  
 role of, in clinical obstetrics, 63-66  
 transcytosis, endothelial barrier in target organs, 97-100  
 trophoblast invasion and, 49-52  
 uterine blood vessels, 55-60  
 in vivo human endometrial morphology, 31-35
- Human menopausal gonadotropin (hMG), superovulation strategies, assisted reproductive technologies (ART), 208-211
- Human studies, nongonadal LH/hCG receptors, pig studies, parallels with, 19-27
- Hybridization techniques, ovarian gene identification, 167-172
- Hyperandrogenic disorders, oral contraceptives for management of, 300
- Hypoestrogenic states, oral contraceptives and protection against, 300
- ICSI. *See* Intracytoplasmic sperm injection (ICSI)
- Implanon, implant contraception using, 339-349
- Implantation  
 embryo transfer, blastocyst *vs.* day 2 or 3 transfer, 259-266  
 human chorionic gonadotropin (hCG) in embryo-endometrial microenvironment, 37-46
- Implant contraception, risks and benefits of, 339-349
- Imprinting, nonrandom X chromosome inactivation, 126-129
- Incontinentia pigmenti (IP), skewed X-chromosome inactivation, X-linked disorders, 188-189
- Infection, LH/hCG receptor function and, 7-12
- Infertility. *See also* Assisted reproductive technologies (ART)  
 assisted reproductive technologies (ART)  
   blastocyst *vs.* embryo transfer, 259-266  
   cost-effectiveness of in vitro fertilization, 279-287  
   intracytoplasmic sperm injection (ICSI), genetic effects, 239-247  
   male infertility strategies, 231-235  
   multiple pregnancies, avoidance of, 269-277  
   oocyte freezing, 221-228  
   research overview, 205  
   single-embryo transfer, 251-257  
   superovulation strategies, 207-211  
   in vitro fertilization, gonadotropin-releasing hormone antagonists and, 213-219
- male infertility  
   intracytoplasmic sperm injection (ICSI), genetic effects, 239-247  
   strategies for, 231-235
- in vitro fertilization  
   blastocyst *vs.* embryo transfer, 259-266  
   cost-effectiveness of, 279-287  
   gonadotropin-releasing hormone antagonists and, 213-219  
   intracytoplasmic sperm injection (ICSI), genetic effects, 239-247  
   male infertility strategies, 234-235  
   multiple pregnancies, avoidance of, 269-277  
   oocyte freezing as alternative to, 221-228  
   single-embryo transfer, multiple pregnancies, 251-257  
   superovulation strategies, 207-211
- in vitro fertilization with embryo transfer (IVF-ET), in vivo endometrial morphology, human chorionic gonadotropin and, 31-35
- Informed patient choice, oral contraceptive compliance and, 313-320
- Injectable contraception, options in U.S. for, 331-335
- Inositol phosphate, LH activation, bovine models, 89-94
- Integrins, human chorionic gonadotropin (hCG), trophoblast invasion, 49-52
- Intracytoplasmic sperm injection (ICSI)  
 cost-effectiveness of, 281-287  
 genetic effects, 239-247  
 male infertility management, 231-235
- Intrauterine devices (IUDs)  
 contraceptive vaginal rings (CVRs) compared with, 382-388  
 emergency contraception using, 323-329  
 progestin-releasing intrauterine systems  
   risks and benefits of, 355-361  
   therapeutic applications, 365-371
- Intrauterine growth retardation (IUGR), LH/hCG receptors, uterine blood vessels, 55-60
- Intrauterine injection (IUI), male infertility strategies, 234-235
- Intrauterine microdialysis (IUMD), human chorionic gonadotropin (hCG) in embryo-endometrial microenvironment, differentiation and implantation, 37-46
- In vitro fertilization  
 blastocyst *vs.* embryo transfer, 259-266  
 cost-effectiveness of, 279-287  
 gonadotropin-releasing hormone antagonists and, 213-219  
 intracytoplasmic sperm injection (ICSI), genetic effects, 239-247  
 male infertility strategies, 234-235  
 multiple pregnancies, avoidance of, 269-277  
 oocyte freezing as alternative to, 221-228  
 single-embryo transfer, multiple pregnancies, 251-257  
 superovulation strategies, 207-211
- In vitro fertilization with embryo transfer (IVF-ET), in vivo endometrial morphology, human chorionic gonadotropin and, 31-35
- In vitro studies, baboon uterine receptivity, chorionic gonadotropin (CG) and, 71-73
- In vivo studies  
 baboon uterine receptivity, chorionic gonadotropin (CG) and, 69-73  
 endometrial morphology, human chorionic gonadotropin and, 31-35  
 rat models, uterine blood vessels, LH/hCG effects on, 78-81
- Iron-deficiency anemia  
 levonorgestrel-releasing intrauterine system (LNG-IUS) for management of, 365-371  
 oral contraceptives and protection against, 298
- Klinefelter syndrome  
 intracytoplasmic sperm injection (ICSI), genetic effects, 245-247  
 neurodevelopment and, 193-201
- Lactating women, implant contraception use in, 347-349
- Lethal mutation, X chromosome molecular and clinical correlates, 123-124



- Levonorgestrel  
 contraceptive vaginal rings (CVRs) using, 382-388  
 emergency contraception using, 323-329  
 implant contraception using, 340-349  
 progestin-releasing intrauterine systems, 355-361  
 transdermal contraception using, 373-379
- Levonorgestrel-releasing intrauterine system (LNG IUS)  
 risks and benefits of, 355-361  
 therapeutic applications, 365-371
- Leydig cells, LH/CG receptors, transendothelial transport, 98-100
- LH. *See* Luteinizing hormone (LH) receptor
- Low-responder stimulation, superovulation strategies, assisted reproductive technologies (ART), 208-210
- Luteal phase supplementation  
 embryo transfer, blastocyst *vs.* day 2 or 3 transfer, 259-266  
 in vitro fertilization, gonadotropin-releasing hormone (GnRH) antagonists, 218-219
- Luteinizing hormone (LH) receptor  
 bovine models, myometrial and vascular receptors, 87-94  
 gonadotropin two-cell theory, 3  
 knockout model, 7-12  
 neural actions, 103-107  
 nongonadal tissue regulation, 5  
 research overview, 7-12  
 pig and human studies, parallels in, 19-27  
 rat models  
 behavioral effects of, 111-118  
 uterine blood vessels, LH/hCG effects on, 75-81  
 role of, in clinical obstetrics, 64-66  
 transcytosis, endothelial barrier in target organs, 97-100  
 uterine blood vessels, 55-60  
 in vivo endometrial morphology, human chorionic gonadotropin and, 31-35
- Lutropin. *See* Luteinizing hormone (LH) receptors
- Lyon's hypothesis, X chromosome inactivation, 126-129
- Magnesium sulfate  
 LH/hCG receptors, uterine blood vessels, 55-60  
 tocolytic therapy using, 63-66
- Male infertility  
 intracytoplasmic sperm injection (ICSI), genetic effects, 239-247  
 strategies for, 231-235
- Male lethal defects, skewed X-chromosome inactivation, X-linked disorders, 188-189
- Mammalian dosage compensation, X chromosome inactivation, 125-129
- Mammary glands, LH/hCG receptors in, 10-12, 27
- Maternal age, assisted reproductive technologies, multiple pregnancies, avoidance of, 271-277
- Maternal behavior, rat models, behavioral effects of hCG and, 111-118
- Medroxyprogesterone acetate (MPA), injectable contraception using, 331-335
- Meiotic spindle, oocyte freezing technology, 226-228
- Melittin, bovine models, prostaglandin production, uterine vein, 91-94
- Menstrual disorders  
 levonorgestrel-releasing intrauterine system (LNG-IUS) for management of, 365-371  
 oral contraceptives for management of, 299-301  
 progestin-releasing intrauterine systems and, 355-361
- Metalloproteinases, human chorionic gonadotropin (hCG), trophoblast invasion, 49-52
- Microarray techniques, ovarian gene identification, 169-172
- Mirena, progestin-releasing intrauterine system, 356-361
- Miscarriage, recurrent spontaneous abortion, X chromosome inactivation, 175-180
- Mitochondrial transmission, intracytoplasmic sperm injection (ICSI), genetic effects, 246-247
- Mitogen-activated protein kinase (MAPK), baboon models, uterine receptivity, chorionic gonadotropin modulation, 71-73
- MLS syndrome, skewed X-chromosome inactivation, X-linked disorders, 188-189
- Monosomy X, Turner syndrome and premature ovarian failure, molecular analysis, 141-145
- Mosaicism  
 skewed X chromosome inactivation, recurrent spontaneous abortion and, 179-180  
 skewed X-chromosome inactivation, X-linked disorders, 187-189
- XXY Klinefelter syndrome, neurodevelopmental abnormalities, 193-201
- Multiple pregnancies  
 avoidance of, in assisted reproductive technologies (ART), 269-277  
 single-embryo transfer and, 251-257  
 in vitro fertilization, cost-effectiveness and, 279-287
- Myocardial infarction, oral contraceptive use and risk of, 307-311
- Myometrium  
 bovine models, myometrial and vascular LH receptors, 87-94  
 LH/hCG receptors in, 22-24  
 rat models, uterine blood vessels, LH/hCG effects on, 80-81
- Neonatal outcomes, in vitro fertilization, gonadotropin-releasing hormone (GnRH) antagonists, 218-219
- Nestorone, contraceptive vaginal rings (CVRs) using, 384-388
- Neurodevelopment, polysomy X Klinefelter syndrome, 193-201
- Neuroendocrine function, LH/hCG receptors in brain, 105-107
- Noncontraceptive benefits  
 injectable contraceptives, 331-335  
 oral contraceptives, 295-301
- Nongonadal actions  
 follicle-stimulating hormone (FSH) receptors in, 93-94  
 LH/hCG regulation, 5  
 baboon models, uterine receptivity, 69-73  
 bovine models, myometrial and vascular receptors, 87-94  
 embryo-endometrial microenvironment, differentiation and implantation, 37-46  
 neural actions, 103-107  
 pig and human studies, parallels in, 19-27  
 rat models, behavioral effects, 111-118  
 rat models, uterine blood flow, 75-81  
 research overview, 7-12  
 transcytosis across endothelial barriers, 97-100  
 trophoblast invasion, 49-52

- Nongonadal actions, LH/hCG regulation (*cont.*)  
uterine blood vessels and, 55-60  
in vivo endometrial morphology, 31-35
- Nonrandom inactivation  
ring X abnormality, X chromosome, inactivation and phenotype, 149-154  
skewed X-chromosome inactivation, X-linked disorders, 186-189  
X chromosomes, 126-129
- Norelgestromin (NGMN), transdermal contraception using, 373-379
- Norethindrone acetate, contraceptive vaginal rings (CVRs) using, 384-388
- Norplant, implant contraception using, 339-349
- "Off-label" practices, noncontraceptive benefits of oral contraceptives, 295-301
- Oocyte freezing, techniques and applications, 221-228
- Oral contraceptives  
emergency contraception using, 323-329  
maximization of access to, 314-320  
noncontraceptive benefits and therapeutic uses, 295-301  
patient compliance and failure rates, 313-320  
risks of, 305-311
- Ortho Evra, transdermal contraception using, 373-379
- Outcomes models, in vitro fertilization, cost-effectiveness, 282-287
- Ovarian blood flow, rat models, uterine blood vessels, LH/hCG effects on, 78-81
- Ovarian cancer, oral contraceptives and prevention of, 296
- Ovarian cysts  
oral contraceptives and protection against, 298-301  
progesterin-releasing intrauterine systems and, 360-361
- Ovarian development, X chromosome molecular and clinical correlates, 124
- Ovarian dysfunction, fragile X syndrome in females, 159-163
- Ovarian failure. *See* Premature ovarian failure (POF)
- Ovarian genes, differential hybridization, other identification strategies, 167-172
- Ovarian hyperstimulation syndrome (OHSS)  
superovulation strategies, assisted reproductive technologies (ART), 208-211  
in vitro fertilization, gonadotropin-releasing hormone (GnRH) antagonists, 213-219
- Ovarian stimulation, superovulation strategies, assisted reproductive technologies (ART), 207-211
- Oviduct function, LH/hCG receptors and, 21-23
- Paracrine tissue invasion, human chorionic gonadotropin (hCG) in embryo-endometrial microenvironment, differentiation and implantation, 43-46
- Parthenogenetic activation, oocyte freezing technology, 227-228
- Patient compliance, oral contraceptive use and, 313-320
- Pelvic inflammatory disease (PID)  
oral contraceptives and reduction of, 296-298  
progesterin-releasing intrauterine systems for management of, 355-361
- Pharmacokinetics  
emergency contraception, 325-329  
implant contraception, 341-349  
transdermal contraception, 373-379
- Pig studies, nongonadal LH/hCG receptors, 19-27  
*PKRX* and *PKRY* genes, X-Y chromosome translocation, 133-138
- Placebo interval, oral contraceptive compliance and, 319-320
- Placentation, human chorionic gonadotropin (hCG) in embryo-endometrial microenvironment, differentiation and implantation, 42-46
- Polycystic ovary syndrome (PCOS), superovulation strategies, assisted reproductive technologies (ART), 210-211
- Polysomy disorders, Klinefelter syndrome, neurodevelopmental abnormalities, 193-201
- Postcoital contraception, emergency contraception techniques, 323-329
- Practice guidelines, oral contraceptive use and compliance rates, 313-320
- Precompacted embryo, embryo transfer, blastocyst *vs.* day 2 or 3 transfer, 261-266
- Pregnancy  
human chorionic gonadotropin (hCG) and  
in embryo-endometrial microenvironment, differentiation and implantation, 45-46  
maintenance of, 63-66  
LH/hCG receptors, 7-12  
uterine blood vessels, 55-60  
multiple pregnancies, single-embryo transfer and, 251-257
- Pregnancy loss. *See* Abortion; Threatened abortion
- Premature luteinization, in vitro fertilization, gonadotropin-releasing hormone (GnRH) antagonists, 213-219
- Premature ovarian failure (POF)  
fragile X syndrome in females, 159-163  
Turner syndrome and premature ovarian failure, molecular analysis, 141-145  
X chromosome molecular and clinical correlates, 124
- Preterm labor, human chorionic gonadotropin (hCG) and pregnancy stabilization, 63-66
- Progestasert, progesterin-releasing intrauterine system, 356-361
- Progesterone  
baboon uterine receptivity, chorionic gonadotropin (CG) and, 70-73  
contraceptive vaginal rings (CVRs), 381-388
- Progesterin-only contraceptives  
contraceptive vaginal rings (CVRs), 381-388  
emergency contraception using, 325-329  
implant contraception using, 339-349  
oral contraceptive compliance and, 318-320  
progesterin-releasing intrauterine systems  
risks and benefits of, 355-361  
therapeutic applications, 365-371
- Prostaglandins  
behavioral effects of hCG and, 111-118  
bovine models, myometrium and cervical LH and FSH receptors, 87-94  
human chorionic gonadotropin receptor function and, 64-66
- Protein structure, luteinizing hormone receptors, 20-23
- Pseudoautosomal region (PAR), X chromosome molecular and clinical correlates, 123-124
- Rat models  
behavioral effects of hCG, 111-118  
LH/hCG effects on uterine blood flow, 75-81



- Receptor function, nongonadal tissue regulation, 7-12
- Recurrent spontaneous abortion, skewed X inactivation and, 175-180
- Representational difference analysis (RDA), ovarian genes, 169-172
- Reproductive counseling, oral contraceptive use and compliance rates, 313-320
- Rett syndrome, skewed X-chromosome inactivation, X-linked disorders, 188-189
- Reverse transcriptase assays, skewed X-chromosome inactivation, X-linked disorders, 185-189
- Rheumatoid arthritis, oral contraceptives as protection from, 299
- Ring X chromosomes, abnormality, X chromosome, inactivation and phenotype, 147-154
- Risk assessment
- injectable contraceptives, 332-335
  - oral contraceptives, 305-311
- Safety analysis
- emergency contraception, 325-329
  - transdermal contraception, 378-379
- Semen analysis, male infertility strategies, 232-235
- Sex chromosomes, X chromosome molecular and clinical correlates, 123-124
- Sex determination, X-Y chromosome translocation, 133-138
- Sex steroid hormones, contraceptive vaginal rings (CVRs) and release of, 381-388
- Sexually transmitted infections (STIs), implant contraception as protection against, 347-349
- SHOX* gene
- ring X abnormality, X chromosome, inactivation and phenotype, 148-154
  - Turner syndrome and premature ovarian failure, molecular analysis, 142-145
- Side effects
- contraceptive vaginal rings (CVRs), 386-388
  - of implant contraception, 339-349
  - injectable contraceptives, 332-335
  - oral contraceptives
    - emergency contraception and, 325-329
    - patient compliance and, 313-320
    - progestin-releasing intrauterine systems, 356-361
- Signaling pathways
- baboon uterine receptivity, chorionic gonadotropin (CG) and, 71-73
  - LH/hCG receptors, neural action of, 106-107
- Single-embryo transfer
- assisted reproductive technologies, multiple pregnancies, avoidance of, 273-277
  - multiple pregnancies, 251-257
- Single-gene identification, ovarian genes, 170
- Skewed X-chromosome inactivation
- recurrent spontaneous abortion and, 175-180
  - X-linked disorders, 183-189
- Sleep patterns, behavioral effects of hCG and, 111-118
- Smoking, risk assessment of oral contraceptive use and, 305-311
- Spermatozoa quality and quantity, male infertility strategies and, 231-235
- Sperm chromatin structure assay (SCSA), male infertility strategies, 232-235
- Sperm function testing, male infertility strategies, 232-235
- Spinal cord regeneration, LH/hCG receptors, neural action of, 106-107
- SRY* gene, X-Y chromosome translocation, 133-138
- Stature genes, Turner syndrome and premature ovarian failure, molecular analysis, 141-145
- Sterilization, levonorgestrel-releasing intrauterine system (LNG-IUS) as replacement for, 368-371
- Stochastic processes
- nonrandom X chromosome inactivation, 126-129
  - skewed X-chromosome inactivation, X-linked disorders, 186-189
- Stress ulcers, rat models, behavioral effects of hCG and, 111-118
- Stroke, risk of, oral contraceptive use and, 305-311
- Stromal fibroblasts, baboon uterine receptivity, chorionic gonadotropin (CG) and, 72-73
- Superovulation strategies, assisted reproductive technologies (ART), 207-211
- Suppression subtractive hybridization (SSH), ovarian genes, identification strategies, 168-172
- Syncytiotrophoblast (STB), human chorionic gonadotropin (hCG) invasion, 49-52
- Tamoxifen, levonorgestrel-releasing intrauterine system (LNG-IUS) combined with, 370-371
- Target organs, LH/CG receptors, transendothelial transport to, 97-100
- Thrombosis
- venous thromboembolic disease, oral contraceptive use and risk of, 308-311
- Tocolytic therapy, human chorionic gonadotropin (hCG) and pregnancy stabilization, 63-66
- Toxic shock syndrome (TSS), oral contraceptives as protection from, 299
- Trancytosis, LH/CG receptors, endothelial barrier in target organs, 97-100
- Transcytotic receptors, LH/CG receptors as, 97-100
- Transdermal contraception, techniques and pharmacokinetics of, 373-379
- Transendothelial transport, LH/CG receptors, 98-100
- Translocation
- X/autosomes, 153-154
  - skewed inactivation, recurrent spontaneous abortion and, 177-180
  - X-Y chromosomes, 133-138
- Trinucleotide repeat, fragile X syndrome in females, 159-163
- Trisomy mosaicism, skewed X chromosome inactivation, recurrent spontaneous abortion and, 179-180
- Trophoblast
- differentiation, human chorionic gonadotropin (hCG) in embryo-endometrial microenvironment, 37-46
  - invasion, human chorionic gonadotropin (hCG), 49-52
- Turner syndrome
- ring X abnormality, X chromosome, inactivation and phenotype, 147-154
  - Xp gene, molecular analysis, 141-145
- Twinning
- assisted reproductive technologies, multiple pregnancies, avoidance of, 276-277
  - fragile X syndrome in females, 159-163
  - single-embryo transfer and, 251-257

- Twinning (*cont.*)  
skewed X-chromosome inactivation, X-linked disorders, 187-189
- Umbilical cord, LH/hCG receptors in, 26-27
- USP9X* gene, premature ovarian failure and, 143-145
- Uterine cancer, oral contraceptives as protection from, 299
- Uterine environment, embryo transfer, blastocyst *vs.* day 2 or 3 transfer, 260-266
- Uterine receptivity  
baboon uterine receptivity, chorionic gonadotropin (CG) and, 69-73  
human chorionic gonadotropin (hCG) and pregnancy stabilization, 63-66
- Uterus  
bovine models, LH stimulation of uterine vein, 91-94  
LH/hCG receptors in, 22-26  
rat models, LH/hCG effects on uterine blood flow, 75-81  
vascular LH/hCG receptors in, 55-60
- Vaginal rings, contraception using, 381-388
- Vascular endothelium, rat models, uterine blood vessels, LH/hCG effects on, 81
- Vascular tissue, prostaglandin production, LH activation, bovine models, 91-94
- Venous thromboembolic disease, oral contraceptive use and risk of, 308-311
- Vitrification, oocyte freezing technology and, 226-228
- X chromosome  
autosome translocations, 153-154  
deletion, duplication and inversions, 153-154  
fragile X syndrome in female patients, 159-162  
molecular and clinical correlates, 123-124  
ovarian gene identification, techniques for, 167-172  
Xp genes, molecular analysis, 141-145  
X-Y translocations, sex determination, 133-138  
X chromosome inactivation (XCI)  
incomplete inactivation, polysomy X Klinefelter syndrome, 193-201  
mammalian dosage compensation, 125-129  
ring X abnormalities, 147-154  
skewed inactivation  
recurrent spontaneous abortion and, 175-180  
X-linked disorders, 183-189  
XIST (Xi-specific transcripts) RNA  
ring X abnormality, X inactivation and phenotype, 148-154  
skewed X-chromosome inactivation, X-linked disorders, 183-189  
X chromosome inactivation, 127-129  
X-linked disorders, skewed X-chromosome inactivation, 183-189  
45,X male phenotype  
ring X abnormality, X chromosome, inactivation and phenotype, 147-154  
X-Y chromosome translocation, 135-138  
Xp chromosome arm  
Turner syndrome and premature ovarian failure, molecular analysis, 141-145  
X chromosome molecular and clinical correlates, 123-124  
Xq chromosome arm, X chromosome molecular and clinical correlates, 123-124  
XXY mutation, polysomy X Klinefelter syndrome, 193-201  
Y chromosome  
damage from intracytoplasmic sperm injection (ICSI), 244-247  
X chromosome molecular and clinical correlates, 123-124  
X-Y translocations, sex determination, 133-138  
Yp chromosome arm, X-Y chromosome translocation, 133-138  
(Y+) XX maleness, X-Y chromosome translocation, 135-138  
Zona pellucida, oocyte freezing technology, 227-228

